FindTrial
Sign In

Study of Medication and Placebo Response in Major Depression

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00229476
Enrollment
60
Registered
2005-09-29
Start date
2003-12-31
Completion date
Unknown
Last updated
2016-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorder, Major

Keywords

Depression, EEG, QEEG, cordance, Zoloft, sertraline, placebo, electroencephalogram, brain, antidepressants

Brief summary

The primary purpose of the research study is to use recordings of brain electrical activity (through electroencephalogram, or EEG) and symptom measurements to determine whether patients are likely to show a response to medication or placebo treatment during a treatment trial for depression.

Interventions

DRUGsertraline (Zoloft)

Sponsors

Eli Lilly and Company
CollaboratorINDUSTRY
Pfizer
CollaboratorINDUSTRY
Massachusetts General Hospital
CollaboratorOTHER
University of California, Los Angeles
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Clinical Diagnosis of Unipolar Major Depression

Exclusion criteria

* Substance Abuse, Psychotic Disorder, History of Severe Head Trauma

Design outcomes

Primary

MeasureTime frame
depressive symptoms—

Secondary

MeasureTime frame
brain electrical activity (EEG)—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026